Literature DB >> 3489051

Circulating T- and B-cell abnormalities in cutaneous lupus erythematosus.

P Kind, P E Lipsky, R D Sontheimer.   

Abstract

Seven patients with subacute cutaneous lupus erythematosus (SCLE), 11 patients with discoid lupus erythematosus (DLE), and 17 age-, sex-, and race-matched controls were examined for the number of circulating peripheral blood T and B cells, immunoglobulin (Ig) synthesizing cells, and Ig secreting cells. A significant alteration in T-cell subsets was detected only in SCLE patients who manifested a decreased number of OKT8 cells. Circulating B cells were significantly increased only in the SCLE patients. The percentage of Ig synthesizing and secreting cells was significantly increased in both the DLE and the SCLE groups. The somewhat unexpected increase in Ig synthesizing and secreting cells in the DLE patients could not be accounted for by antimalarial treatment or the concurrence of the HLA-DR3 phenotype. There was, however, a weak but significant correlation between the degree of B-cell activation in the DLE patients and the number of American Rheumatism Association criteria for the classification of systemic lupus erythematosus (SLE) possessed by these patients. These data demonstrate that abnormalities in B-cell function similar to those seen in SLE can also be found in a group of lupus erythematosus patients whose clinical disease expression is limited predominantly to the skin.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3489051     DOI: 10.1111/1523-1747.ep12285191

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  4 in total

1.  Use of cultured epithelial cells, including keratinocytes, for the detection of antinuclear antibodies.

Authors:  I Leigh; F Wojnarowska; S Burge; B Bhogal; T Zhu
Journal:  Ann Rheum Dis       Date:  1987-12       Impact factor: 19.103

2.  Lenalidomide therapy in treatment-refractory cutaneous lupus erythematosus: histologic and circulating leukocyte profile and potential risk of a systemic lupus flare.

Authors:  Inbal Braunstein; Noah G Goodman; Misha Rosenbach; Joyce Okawa; Asha Shah; Michael Krathen; Carrie L Kovarik; Eline Luning Prak; Victoria P Werth
Journal:  J Am Acad Dermatol       Date:  2011-08-06       Impact factor: 11.527

Review 3.  Effects of rituximab-based B-cell depletion therapy on skin manifestations of lupus erythematosus--report of 17 cases and review of the literature.

Authors:  S C Hofmann; M J Leandro; S D Morris; D A Isenberg
Journal:  Lupus       Date:  2013-08       Impact factor: 2.911

4.  Expression of BAFF and BR3 in patients with systemic lupus erythematosus.

Authors:  J H Duan; Y Jiang; H Mu; Z Q Tang
Journal:  Braz J Med Biol Res       Date:  2016-02-02       Impact factor: 2.590

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.